A Randomized, Dose-Ranging, Placebo-Controlled, 84-Day Study Of INCB039110, a Selective Janus Kinase-1 Inhibitor, In Patients With Active Rheumatoid Arthritis

被引：0
|
作者：
Luchi, Monica [1 ]
Fidelus-Gort, Rosanne [1 ]
Douglas, Diane [1 ]
Zhang, Haifeng [1 ]
Flores, Robert [1 ]
Newton, Robert [1 ]
Scherle, Peggy [1 ]
Yeleswaram, Swamy [1 ]
Chen, Xuejun [1 ]
Sandor, Victor [1 ]
机构：
[1] Incyte Corp, Wilmington, DE USA
来源：
ARTHRITIS AND RHEUMATISM | 2013年 / 65卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1797
引用
收藏
页码：S765 / S766
页数：2
相关论文
共 50 条
  • [1] A randomized, double-blind, placebo-controlled, dose-escalation study of the safety and efficacy of INCB039110, an oral janus kinase 1 inhibitor, in patients with stable, chronic plaque psoriasis
    Bissonnette, Robert
    Luchi, Monica
    Fidelus-Gort, Rosanne
    Jackson, Shawnta
    Zhang, Haifeng
    Flores, Robert
    Newton, Robert
    Scherle, Peggy
    Yeleswaram, Swamy
    Chen, Xuejun
    Menter, Alan
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2016, 27 (04) : 332 - 338
  • [2] A Randomized placebo-controlled study of INCB018424, a selective janus kinase 1 & 2 (JAK1&2) inhibitor in rheumatoid arthritis (RA)
    Williams, William
    Scherle, Peggy
    Shi, Jack
    Newton, Robert
    McKeever, Edward
    Fridman, Jordan
    Burn, Timothy
    Vaddi, Kris
    Levy, Richard
    Moreland, Larry
    ARTHRITIS AND RHEUMATISM, 2008, 58 (09): : S431 - S431
  • [3] Efficacy and safety of the oral Janus kinase 1 inhibitor povorcitinib (INCB054707) in patients with hidradenitis suppurativa in a phase 2, randomized, double-blind, dose-ranging placebo-controlled study
    Kirby, Joslyn S.
    Okun, Martin M.
    Alavi, Afsaneh
    Bechara, Falk G.
    Zouboulis, Christos C.
    Brown, Kurt
    Santos, Leandro L.
    Wang, Annie
    Bibeau, Kristen B.
    Kimball, Alexa B.
    Porter, Martina L.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2024, 90 (03) : 521 - 529
  • [4] A Randomized, Double-Blind, Placebo-Controlled, Twelve-Week, Dose-Ranging Study of Decernotinib, an Oral Selective JAK-3 Inhibitor, as Monotherapy in Patients With Active Rheumatoid Arthritis
    Fleischmann, Roy M.
    Damjanov, Nemanja S.
    Kivitz, Alan J.
    Legedza, Anna
    Hoock, Thomas
    Kinnman, Nils
    ARTHRITIS & RHEUMATOLOGY, 2015, 67 (02) : 334 - 343
  • [5] Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study
    Papp, K. A.
    Menter, A.
    Strober, B.
    Langley, R. G.
    Buonanno, M.
    Wolk, R.
    Gupta, P.
    Krishnaswami, S.
    Tan, H.
    Harness, J. A.
    BRITISH JOURNAL OF DERMATOLOGY, 2012, 167 (03) : 668 - 677
  • [6] Efficacy and Safety of Belimumab in Patients with Rheumatoid Arthritis: A Phase II, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study
    Stohl, William
    Merrill, Joan T.
    McKay, James D.
    Lisse, Jeffrey R.
    Zhong, Z. John
    Freimuth, William W.
    Genovese, Mark C.
    JOURNAL OF RHEUMATOLOGY, 2013, 40 (05) : 579 - 589
  • [7] A randomized, placebo-controlled, phase 2 study of the Janus Kinase 1 inhibitor INCB054707 for patients with moderate-to-severe hidradenitis suppurativa
    Alavi, Afsaneh
    Hamzavi, Iltefat
    Brown, Kurt
    Santos, Leandro L.
    Zhu, Zhaoyin
    Howell, Michael D.
    Kirby, Joslyn
    EXPERIMENTAL DERMATOLOGY, 2021, 30 : 69 - 70
  • [8] Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: A randomized, double-blind, placebo-controlled, dose-ranging study (vol 58, pg 964, 2008)
    Kay
    ARTHRITIS AND RHEUMATISM, 2010, 62 (11): : 3518 - 3518
  • [9] A phase 1, randomized, placebo-controlled, 3-day, dose-ranging study of GS-5885, an NS5A inhibitor, in patients with genotype 1 hepatitis C
    Lawitz, Eric J.
    Gruener, Daniel
    Hill, John M.
    Marbury, Thomas
    Moorehead, Lisa
    Mathias, Anita
    Cheng, Guofeng
    Link, John O.
    Wong, Kelly A.
    Mo, Hongmei
    McHutchison, John G.
    Brainard, Diana M.
    JOURNAL OF HEPATOLOGY, 2012, 57 (01) : 24 - 31
  • [10] The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment - Results of a phase IIb randomized, double-blind, placebo-controlled, dose-ranging trial
    Emery, P
    Fleischmann, R
    Filipowicz-Sosnowska, A
    Schechtman, J
    Szczepanski, L
    Kavanaugh, A
    Racewicz, AJ
    Van Vollenhoven, RF
    Li, NF
    Agarwal, S
    Hessey, EW
    Shaw, TM
    ARTHRITIS AND RHEUMATISM, 2006, 54 (05): : 1390 - 1400
12345